Success Metrics

Clinical Success Rate
100.0%

Based on 36 completed trials

Completion Rate
100%(36/36)
Active Trials
0(0%)
Results Posted
75%(27 trials)

Phase Distribution

Ph phase_2
10
25%
Ph phase_3
13
33%
Ph not_applicable
1
3%
Ph phase_4
15
38%

Phase Distribution

0

Early Stage

10

Mid Stage

28

Late Stage

Phase Distribution39 total trials
Phase 2Efficacy & side effects
10(25.6%)
Phase 3Large-scale testing
13(33.3%)
Phase 4Post-market surveillance
15(38.5%)
N/ANon-phased studies
1(2.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.7%

36 of 38 finished

Non-Completion Rate

5.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

40

all time

Status Distribution
Completed(36)
Terminated(2)
Other(2)

Detailed Status

Completed36
Withdrawn2
Suspended1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
40
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 210 (25.6%)
Phase 313 (33.3%)
Phase 415 (38.5%)
N/A1 (2.6%)

Trials by Status

withdrawn25%
suspended13%
unknown13%
completed3690%

Recent Activity

Clinical Trials (40)

Showing 20 of 40 trialsScroll for more
NCT07541378Not Applicable

Comparative Efficacy of Once-daily LAMA/LABA Combinations Versus Tiotropium on Constant-work-rate Cycle Endurance in COPD

Suspended
NCT05506865Phase 4

Efficacy and Safety of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass Exposure

Completed
NCT02872090Phase 4

Effects of Long Acting Bronchodilators on CARDiac Autonomic Control in Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02598505Phase 3

Indacaterol in Heart Failure Patients: Any Role on Lung Fluid Regulation

Completed
NCT03030638

Drug Utilization Study for Olodaterol

Completed
NCT02039011Phase 4

Ultra-long Acting Bronchodilator Therapy in Asthmatics

Completed
NCT00570778Phase 2

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed
NCT02257385Phase 3

Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium

Completed
NCT02418468Phase 4

Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations

Completed
NCT02953041Phase 4

Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve

Completed
NCT01715311Phase 4

Comparison of Indacaterol With That of Placebo in 'Maintenance naïve' Patients With COPD Using Blinded Tiotropium as Active Control

Withdrawn
NCT01377428Phase 4

Efficacy of Indacaterol 150 µg Versus Formoterol

Withdrawn
NCT02055352Phase 4

Study to Evaluate Efficacy/Safety of Combination Budesonide/Indacaterol vs Fluticasone/Salmeterol in Patients With COPD

Completed
NCT01727024Phase 4

Study Evaluating Preference, Satisfaction And Correct Use Of Inhalers In COPD Patients

Completed
NCT01272362Phase 4

To Determine the Relationship Between Baseline Reversibility and the Efficacy of Indacaterol

Completed
NCT01012765Phase 3

Effect of Indacaterol on Inspiratory Capacity (IC)

Completed
NCT01778062Phase 3

Indacaterol EfectIveness In COPD Patients With Tuberculosis History

Completed
NCT02473237Phase 4

Efficacy in Walked Distance of Indacaterol vs Tiotropium in Women With COPD Secondary to Biomass (EMERALD)

Completed
NCT02547558Phase 4

Pulmonary Gas Exchange Response to Indacaterol in COPD

Unknown
NCT01555138Phase 4

Comparison of Indacaterol 150 mcg Once Daily (o.d.) With Salmeterol/Fluticasone Propionate 50 mcg/500 mcg Twice Daily (b.i.d.)

Completed

Drug Details

Intervention Type
DRUG
Total Trials
40